ArticleInfectious diseases of poverty2026
Development and validation of a machine learning-based model for identifying liver fibrosis in individuals with prior Schistosoma japonicum infection: a step toward precision management.
Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLiver fibrosis caused by Schistosoma japonicum may continue to progress even following successful praziquantel chemotherapy. Although liver biopsy remains the gold standard for diagnosis of liver fibrosis, its invasiveness limits clinical applications. Conventional non-invasive indices, such as aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) index, often show suboptimal performance in schistosomiasis-related cases. This study aimed to develop and validate a machine learning (ML)-based model using epidemiological and laboratory data to identify liver fibrosis in individuals with prior S. japonicum infection, as a step toward precision management.
methodsData were obtained from the Jiangsu S. japonicum Infection Cohort (Jiangsu Province, China), involving 6158 participants with a documented history of infection who completed follow-up assessments during 2021-2022. Modeling variables were selected using LASSO regression and variance inflation factor analysis. Five ML models (k-nearest neighbor, logistic regression, support vector machine, decision tree, and extreme gradient boosting (XGBoost)) were evaluated. Model performance was compared against APRI and FIB-4 using the area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), and shapley additive explanations (SHAP) for interpretability.
resultsIn the validation set, the XGBoost model demonstrated the highest diagnostic performance with an AUC of 0.854 (95% confidence interval (CI): 0.826-0.881), outperforming other ML models (AUC range: 0.609-0.776). This was significantly superior to FIB-4 (AUC = 0.514) and APRI (AUC = 0.516) (P < 0.001). DCA confirmed that the XGBoost model provided a substantial clinical net benefit across a broad range of threshold probabilities. According to Shapley additive explanations analysis, variables such as alcohol intake (mean SHAP value = 0.401), gamma-glutamyl transferase (0.295), and triglycerides (0.292) were the most influential predictors of liver fibrosis risk.
conclusionsThe XGBoost-based model offers a robust, non-invasive tool for identifying liver fibrosis in individuals with prior S. japonicum infection, with alcohol intake, gamma-glutamyl transferase, and triglycerides identified as the critical predictors. By outperforming traditional indices and leveraging routinely available data, this model represents a promising advancement toward precision management of individuals with prior S. japonicum infection, offering a scalable approach for early intervention, risk‑stratified assessment, and monitoring of hepatic morbidity in post‑transmission settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.